Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

By P. Hoff, R. Ansari, G. Batist, John Cox, W. Kocha, M. Kuperminc, J. Maroun, D. Walde, C. Weaver, Evelyn Harrison and 4 more. Journal of Clinical Oncology, 2001

1,163 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/a930659969b479b4ce557799daee811a65502e5f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

S. Clarke

Citations in the corpus

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. (2008, methodology): “The noninferiority margin of 1.23 corresponds to retention of at least 50% of the benefit that oxaliplatin plus FU/FA has shown over FU/FA alone in the first-line treatment of MCRC.”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, positive): “(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient ”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, neutral): “Recommended therapies (CQ‑15) The postoperative adjuvant chemotherapy regimens that were shown to be useful in clinical trials and which are cov‑ ered by the Japanese National Health Insurance program are as follows: Oxaliplatin (OX) combination therapy CAPOX(Preferred)* FOLFOX (Preferred)* Fluoropy”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015, neutral): “Note 1 FOLFOX—infusional 5-FU + l-LV + OX Note 2 CapeOX—Cape + OX Note 3 FOLFIRI—infusional 5-FU + l-LV + RI Note 4 FOLFOXIRI—Infusional 5-FU + l-LV + IRI + OX Note 5 IRIS—S-1 + IRI Chapter 6: Radiotherapy • Radiotherapy is used to treat patients with locally advanced rectal cancer, either as adjuva”
[Systemic therapy for colorectal cancer]. (2005, background): “These two randomized trials, and others with oral fluoropyrimidines, suggest that UFT/LV and capecitabine provide an equally effective, but safer, oral alternative to the standard intravenous bolus 5FU/LV regimen for metastatic colorectal cancer (38,39).”